IP Library Granted Patent US 7,999,105
Granted Patent B2
US 7,999,105 · App. 12/372,788 · Granted Aug 16, 2011

Process for the preparation of 3-hydroxymorphinan derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,999,105
App. No.
12/372,788
Granted
Aug 16, 2011
Kind
B2
Abstract

Processes are described for the synthesis of 3-hydroxymorphinan derivatives by hydrolysis of side products from the O-demethylation of 3-methoxymorphinan derivatives.

Claims (63)

1. A process for the preparation of a morphinan compound (III) corresponding to the formula:

the process comprising hydrolyzing a compound (I) corresponding to the formula:

in a protic solvent to form an intermediate compound (II) corresponding to the formula:

and

heating a mixture comprising an aqueous solvent and the compound (II), at a pH of about 1 to about 6, to form compound (III), wherein

R is selected from the group consisting of hydrogen, alkyl, aryl, acyl, —SR 4 , —OR 4 , and —NR 4 R 5 ;

R 1 and R 2 are independently selected from the group consisting of hydrogen, alkyl, B(OH) 2 , and R 1 and R 2 , along with the atoms to which they are attached, form a 5-membered ring having a fifth ring member B(OH); provided, however, that at least one of R 1 and R 2 is B(OH) 2 or that R 1 and R 2 form the 5-membered ring;

R 3 is selected from the group consisting of hydrocarbyl, substituted hydrocarbyl, and a nitrogen protecting group;

R 4 and R 5 are independently selected from the group consisting of hydrogen, alkyl, aryl, and acyl;

R 6 and R 7 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, NH 2 , SH, hydrocarbyl, and substituted hydrocarbyl, wherein R 6 and R 7 may together form a group selected from the group consisting of ═O and ═S;

R 8 and R 9 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, NH 2 , CN, hydrocarbyl, and substituted hydrocarbyl; and

X is selected from the group consisting of chloro, bromo, and iodo.

2. The process of claim 1 , wherein R 3 is selected from the group consisting of alkyl, allyl, aryl, and acyl.

3. The process of claim 1 , wherein the protic solvent is selected from the group consisting of water, methanol, ethanol, isopropyl alcohol, and combinations thereof, the mixture is heated to a temperature of about 60° C. to about 90° C.; the mixture is adjusted to a pH of about 2 to about 4; X is bromo; R 3 is alkyl; R is selected from the group consisting of hydrogen and hydroxyl; R 7 is methyl; and R 8 is hydroxyl.

4. The process of claim 1 , wherein one of R 1 and R 2 is hydrogen and the other of R 1 and R 2 is B(OH) 2 or R 1 and R 2 , together with the atoms to which they are attached, form the 5-membered ring.

5. The process of claim 1 , wherein the optical activity of compounds (I), (II), and (III) is (−) or (+), and the configuration of C13, C14, and C9, respectively, of compounds (I) and (II) is selected from the group consisting of RRR, RRS, RSR, RSS, SRR, SRS, SSR, and SSS, and the configuration of C5, C13, C14, and C9, respectively, of compound (III) is selected from the group consisting of RRRR, RRSR, RRRS, RRSS, RSRR, RSSR, RSRS, RSSS, SRRR, SRSR, SRRS, SRSS, SSRR, SSSR, SSRS, and SSSS.

6. A process for the preparation of a morphinan compound (III) corresponding to the formula:

the process comprising heating a mixture comprising an aqueous solvent and a compound (II) corresponding to the formula:

at a pH of about 1 to about 6 to form compound (III), wherein:

R is selected from the group consisting of hydrogen, alkyl, aryl, acyl, —SR 4 , —OR 4 , and —NR 4 R 5 ;

R 3 is selected from the group consisting of hydrocarbyl, substituted hydrocarbyl, and a nitrogen protecting group;

R 4 and R 5 are independently selected from the group consisting of hydrogen, alkyl, aryl, and acyl;

R 6 and R7 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, NH 2 , SH, hydrocarbyl, and substituted hydrocarbyl, wherein R 6 and R 7 may together form a group selected from the group consisting of ═O and ═S;

R 8 and R 9 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, NH 2 , CN, hydrocarbyl, and substituted hydrocarbyl; and

X is selected from the group consisting of chloro, bromo, and iodo.

7. The process of claim 6 , wherein R 3 is selected from the group consisting of alkyl, allyl, aryl, and acyl.

8. The process of claim 6 , wherein the mixture is heated to a temperature of about 60° C. to about 90° C.; the mixture is adjusted to a pH of about 2 to about 4; X is bromo; R 3 is alkyl; and R is selected from the group consisting of hydrogen and hydroxyl.

9. The process of claim 6 , wherein the optical activity of compounds (I), (II), and (III) is (−) or (+), and the configuration of C13, C14, and C9, respectively, of compounds (I) and (II) is selected from the group consisting of RRR, RRS, RSR, RSS, SRR, SRS, SSR, and SSS, and the configuration of C5, C13, C14, and C9, respectively, of compound (III) is selected from the group consisting of RRRR, RRSR, RRRS, RRSS, RSRR, RSSR, RSRS, RSSS, SRRR, SRSR, SRRS, SRSS, SSRR, SSSR, SSRS, and SSSS.

10. A morphinan compound, or pharmaceutically acceptable salt thereof, the compound corresponding to the formula:

wherein:

R is selected from the group consisting of hydrogen, alkyl, aryl, acyl, —SR 4 , —OR 4 , and —NR 4 R 5 ;

R 3 is selected from the group consisting of alkyl, aryl, acyl, and a nitrogen protecting group;

R 4 and R 5 are independently selected from the group consisting of hydrogen, alkyl, aryl, and acyl;

R 6 and R 7 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, NH 2 , SH, hydrocarbyl, and substituted hydrocarbyl, wherein R 6 and R 7 may together form a group selected from the group consisting of ═O and ═S;

R 8 and R 9 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, NH 2 , CN, hydrocarbyl, and substituted hydrocarbyl; and

X is selected from the group consisting of chloro, bromo, and iodo.

11. The compound of claim 10 , wherein X is bromo; R 3 is alkyl; and R is selected from the group consisting of hydrogen and hydroxyl.

12. The compound of claim 11 , wherein R 3 is selected from the group consisting of methyl, cyclopropyl, isobutyl, and cyclobutyl.

13. The compound of claim 10 comprising the structure:

wherein:

R 6 and R 7 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, NH 2 , SH, hydrocarbyl, and substituted hydrocarbyl, wherein R 6 and R 7 may together form a group selected from the group consisting of ═O and ═S; and

R 8 and R 9 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, NH 2 , CN, hydrocarbyl, and substituted hydrocarbyl.

14. The compound of claim 10 , wherein the optical activity of the compound is (−) or (+), and the configuration of C13, C14, and C9, respectively, is selected from the group consisting of RRR, RRS, RSR, RSS, SRR, SRS, SSR, and SSS.

15. A morphinan compound, or pharmaceutically acceptable salt thereof, the compound corresponding to the formula:

wherein:

R is selected from the group consisting of hydrogen, alkyl, aryl, acyl, —SR 4 , —OR 4 , and —NR 4 R 5 ;

R 1 and R 2 are independently selected from the group consisting of hydrogen, alkyl, B(OH) 2 , and R 1 and R 2 , along with the atoms to which they are attached, form a 5-membered ring having a fifth ring member B(OH); provided, however, that at least one of R 1 and R 2 is B(OH) 2 or that R 1 and R 2 form the 5-membered ring;

R 3 is selected from the group consisting of alkyl, aryl, acyl, and a nitrogen protecting group;

R 4 and R 5 are independently selected from the group consisting of hydrogen, alkyl, aryl, and acyl;

R 6 and R 7 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, NH 2 , SH, hydrocarbyl, and substituted hydrocarbyl, wherein R 6 and R 7 may together form a group selected from the group consisting of ═O and ═S;

R 8 and R 9 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, NH 2 , CN, hydrocarbyl, and substituted hydrocarbyl; and

X is selected from the group consisting of chloro, bromo, and iodo.

16. The compound of claim 15 , wherein X is bromo; R 3 is alkyl; and R is selected from the group consisting of hydrogen and hydroxyl.

17. The compound of claim 16 , wherein R 3 is selected from the group consisting of methyl, cyclopropyl, isobutyl, and cyclobutyl.

18. The compound of claim 15 having the structure:

wherein:

R 6 and R 7 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, NH 2 , SH, hydrocarbyl, and substituted hydrocarbyl, wherein R6 and R 7 may together form a group selected from the group consisting of ═O and ═S; and

R 8 and R 9 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, NH 2 , CN, hydrocarbyl, and substituted hydrocarbyl.

19. The compound of claim 15 having the structure:

wherein:

R 6 and R 7 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, NH 2 , SH, hydrocarbyl, and substituted hydrocarbyl, wherein R 6 and R7 may together form a group selected from the group consisting of ═O and ═S; and

R 8 and R 9 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, NH 2 , CN, hydrocarbyl, and substituted hydrocarbyl.

20. The compound of claim 15 , wherein the optical activity of the compound is (−) or (+), and the configuration of C13, C14, and C9, respectively, is selected from the group consisting of RRR, RRS, RSR, RSS, SRR, SRS, SSR, and SSS.

Assignments (11)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →